US halts use of GSK/Vir monoclonal in 8 states as FDA says it can’t defeat new Omicron subvariant

With the emergence of the new but not necessarily more dangerous Omicron subvariant BA.2, the FDA on Friday announced that GlaxoSmithKline and Vir’s blockbuster monoclonal antibody to treat Covid-19 will no longer be used in 8 states in the Northeast and two US territories.

New data included in the FDA’s...

Click to view original post